Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bifidobacterium and Lactobacillus enrichment
- Molecular classification
- null (no single molecular classification; both are genera under Bacteria: Bifidobacterium [phylum Actinobacteria] and Lactobacillus [phylum Firmicutes])
01
Overview
Bifidobacterium and Lactobacillus enrichment refers to the process of increasing the abundance of two major genera of probiotic bacteria, Bifidobacterium and Lactobacillus, in the gut microbiome via supplementation or dietary interventions. These bacteria are essential members of the normal intestinal flora, especially in infants, and are associated with diverse health benefits including improving gut barrier function, fermenting indigestible carbohydrates to yield beneficial metabolites (short-chain fatty acids), stimulating immune regulation, and protecting against gastrointestinal infections. Although these bacteria are frequently therapeutic agents in probiotic formulations, "enrichment" itself is not considered a single molecular target but rather a therapeutic goal pursued for prevention or management of several conditions linked to dysbiosis.
- Other names
- Probiotic bacterial enrichmentGut microbiome modulation with Bifidobacterium and LactobacillusBifidobacterium/Lactobacillus supplementationProbiotic strain enrichment
02
Mechanism of action
Colonization resistance: Outcompetes pathogenic microbes Production of antimicrobial metabolites (lactic acid, bacteriocins, SCFAs) Immunomodulation (promoting regulatory rather than proinflammatory responses) Enhancement of mucosal IgA production
03
Biological functions
Maintenance of gut microbial balanceShort-chain fatty acid productionFermentation of dietary carbohydratesImmunomodulationEnhancement of mucosal barrier functionReduction of pathogen colonization
04
Disease associations
Gastrointestinal infection and diarrhea preventionModulation of inflammationAllergic diseaseDysbiosis-associated conditionsPossibly metabolic syndrome and neurodevelopmental disorders
05
Safety considerations
Rare probiotic-associated infections in severely immunocompromised patientsProduct variability and lack of regulatory standardizationPotential for strain-specific effects leading to unpredictable outcomes
06
Interacting drugs
Probiotic mixtures/brands containing Bifidobacterium and Lactobacillus (e.g., Culturelle, Florajen3, Nature's Bounty Probiotic, Primadophilus Bifidus)
07
Biomarkers
Fecal abundance of Bifidobacterium and Lactobacillus (measured via sequencing or culture)Short-chain fatty acid levels (e.g., acetate, lactate)Reduction of pathogenic bacterial markersMicrobiome diversity and composition metrics
Beyond the preview
Go deeper on Bifidobacterium and Lactobacillus enrichment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium and Lactobacillus enrichment.